Fourth Dose Of Variant-Adapted Bivalent COVID-19 Vaccine Has Favorable Benefit-Risk Profile In Young Children, Research Finds

Infectious Disease Advisor (7/10, Basilio) reports, “A fourth dose of a variant-adapted bivalent COVID-19 vaccine has a favorable benefit-risk profile in young children, according to ongoing research.” The research found “that the fourth dose of bivalent BNT162b2 induced a robust immune response in the study patients.” Furthermore, it “met the predefined immunogenicity criteria for superiority and noninferiority against the studied strains when compared with data captured from the matched comparator cohort.” The findings were published in the Journal of the Pediatric Infectious Diseases Society.